Shire receives European approval for label extension of Cinryze
Shire announced that the European Commission has approved a label extension granting three new indications for Cinryze, broadening its use to children with Hereditary angiodema, a rare, genetic disorder that results in recurring attacks of edema. The body sites most commonly affected are mainly the extremities and abdomen. Cinryze is now indicated for routine prevention of angioedema attacks in children with severe and recurrent attacks of HAE who are intolerant to or insufficiently protected by oral preventions treatments, or patients who are inadequately managed with repeated acute treatment. Cinryze is also now approved for the treatment and pre-procedure prevention of angioedema attacks in children with HAE. Cinryze has been approved since 2011 for these indications in adults and adolescents ages 12-17 years with HAE. Cinryze will be available for use in paediatric patients later in 2017 throughout Member States of the European Union, as well the European Economic Area in which Shire currently has a licence in the adult and adolescent population.